BrainStorm to Present at Multiple Scientific Conferences in October
NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)-- BrainStorm Cell Therapeutics (BCLI.OB) (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it is presenting at multiple scientific conferences this month.
Israel Stem Cell Society 5th International Stem Cell Meeting
Professor Dani Offen, BrainStorms Chief Scientific Advisor, will present at the 5th International Stem Cell Meeting sponsored by the Israel Stem Cell Society, October 8th-9th in Jerusalem. Prof. Offen will be making a poster presentation on October 8th at 17:30, and an oral presentation on Oct 9th at 17:15.
Israel Braintech 2013
Professor Dani Offen, BrainStorms Chief Scientific Advisor, will present at the Israel Braintech 2013 Meeting, October 14th-15th in Tel Aviv. The meeting is sponsored by Israel Brain Technologies (IBT), a non-profit organization inspired by the vision of Israeli President Shimon Peres to promote Israels neurotechnology innovation hub. Prof. Offens oral presentation will be part of the session entitled: A Spotlight on the Israeli NeuroTech Industry, October 15th at 12:15.
Israel A.L.S Research Association
Professor Dimitrios Karussis, Principal Investigator of BrainStorms clinical trials at Jerusalems Hadassah Medical Center, will present at the Israel A.L.S Research Association (IsrA.L.S) Conference, From the Lab to the Clinic: An Overview of Current ALS Research in Israel, to be held October 30th at the Weizmann Institute of Science, Rechovot, Israel. Prof. Karussis oral presentation will be at 10:45 a.m.
About BrainStorm Cell Therapeutics, Inc.
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. For more information, visit the companys website at www.brainstorm-cell.com.
Safe Harbor Statement
Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as may, should, would, could, will, expect, likely, believe, plan, estimate, predict, potential, and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorms forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or managements beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.
BrainStorm Cell Therapeutics Inc. (OTC.QB: BCLI)
Mr. Chaim Lebovits, President
Source: BrainStorm Cell Therapeutics Inc.Copyright Business Wire 2013